John Arcaroli
Concepts (359)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Colorectal Neoplasms | 19 | 2018 | 621 | 2.890 |
Why?
| Xenograft Model Antitumor Assays | 20 | 2018 | 706 | 1.590 |
Why?
| Antineoplastic Agents | 17 | 2018 | 1897 | 1.500 |
Why?
| Drug Resistance, Neoplasm | 7 | 2016 | 642 | 1.180 |
Why?
| Benzodioxoles | 3 | 2012 | 84 | 1.100 |
Why?
| Quinazolines | 4 | 2012 | 243 | 1.060 |
Why?
| Camptothecin | 4 | 2016 | 98 | 0.960 |
Why?
| Receptor, Notch1 | 3 | 2015 | 61 | 0.910 |
Why?
| Aldehyde Dehydrogenase | 6 | 2017 | 134 | 0.890 |
Why?
| Mice, Nude | 15 | 2018 | 635 | 0.810 |
Why?
| Haplotypes | 4 | 2012 | 453 | 0.800 |
Why?
| Phosphatidylinositol 3-Kinases | 9 | 2018 | 330 | 0.720 |
Why?
| Gene Dosage | 3 | 2015 | 134 | 0.670 |
Why?
| Wnt Signaling Pathway | 4 | 2015 | 147 | 0.640 |
Why?
| src-Family Kinases | 3 | 2017 | 88 | 0.630 |
Why?
| Amyloid Precursor Protein Secretases | 3 | 2014 | 73 | 0.630 |
Why?
| Protein Kinase Inhibitors | 9 | 2018 | 796 | 0.620 |
Why?
| Enzyme Inhibitors | 5 | 2016 | 752 | 0.620 |
Why?
| Anilides | 2 | 2018 | 67 | 0.620 |
Why?
| Biomarkers, Tumor | 9 | 2018 | 1054 | 0.610 |
Why?
| Neutrophils | 11 | 2007 | 1164 | 0.600 |
Why?
| Mice | 38 | 2018 | 14936 | 0.570 |
Why?
| Endotoxemia | 8 | 2004 | 82 | 0.570 |
Why?
| Pancreatic Neoplasms | 5 | 2016 | 733 | 0.540 |
Why?
| Acute Lung Injury | 2 | 2011 | 300 | 0.540 |
Why?
| Receptors, Notch | 2 | 2015 | 85 | 0.540 |
Why?
| Cell Line, Tumor | 20 | 2018 | 2725 | 0.530 |
Why?
| Tankyrases | 1 | 2016 | 14 | 0.530 |
Why?
| Pyridines | 3 | 2018 | 425 | 0.510 |
Why?
| Drug Discovery | 1 | 2016 | 124 | 0.510 |
Why?
| Polymorphism, Genetic | 3 | 2007 | 612 | 0.490 |
Why?
| 3' Untranslated Regions | 2 | 2012 | 129 | 0.480 |
Why?
| NF-kappa B | 12 | 2007 | 637 | 0.480 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 159 | 0.470 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.470 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2014 | 69 | 0.460 |
Why?
| Tetrahydronaphthalenes | 1 | 2013 | 31 | 0.430 |
Why?
| Valine | 1 | 2013 | 72 | 0.430 |
Why?
| Animals | 41 | 2018 | 31839 | 0.420 |
Why?
| Signal Transduction | 17 | 2018 | 4525 | 0.390 |
Why?
| Sepsis | 3 | 2007 | 508 | 0.390 |
Why?
| Lipopolysaccharides | 9 | 2007 | 817 | 0.380 |
Why?
| Superoxide Dismutase | 3 | 2008 | 305 | 0.360 |
Why?
| Urokinase-Type Plasminogen Activator | 2 | 2007 | 28 | 0.350 |
Why?
| Proto-Oncogene Proteins | 7 | 2018 | 611 | 0.340 |
Why?
| Neoplasm Metastasis | 4 | 2016 | 530 | 0.340 |
Why?
| Hemorrhage | 6 | 2004 | 618 | 0.340 |
Why?
| Interleukins | 1 | 2011 | 236 | 0.330 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 77 | 0.320 |
Why?
| Cell Proliferation | 12 | 2018 | 2199 | 0.320 |
Why?
| Heterografts | 3 | 2018 | 117 | 0.310 |
Why?
| HCT116 Cells | 4 | 2018 | 71 | 0.300 |
Why?
| SOXB1 Transcription Factors | 2 | 2018 | 61 | 0.280 |
Why?
| Mutation | 3 | 2012 | 3354 | 0.280 |
Why?
| Azepines | 2 | 2018 | 74 | 0.280 |
Why?
| Promoter Regions, Genetic | 1 | 2011 | 1133 | 0.280 |
Why?
| Benzimidazoles | 3 | 2013 | 138 | 0.280 |
Why?
| Immunoblotting | 5 | 2015 | 283 | 0.260 |
Why?
| Apoptosis | 10 | 2018 | 2371 | 0.260 |
Why?
| Humans | 45 | 2018 | 114937 | 0.250 |
Why?
| beta Catenin | 3 | 2016 | 220 | 0.250 |
Why?
| Receptors, Interleukin-1 | 1 | 2006 | 227 | 0.240 |
Why?
| Neutrophil Activation | 5 | 2003 | 94 | 0.240 |
Why?
| TOR Serine-Threonine Kinases | 4 | 2018 | 359 | 0.240 |
Why?
| Pyrimidines | 2 | 2018 | 378 | 0.240 |
Why?
| Oligonucleotide Array Sequence Analysis | 6 | 2015 | 744 | 0.230 |
Why?
| Mitogen-Activated Protein Kinases | 6 | 2014 | 278 | 0.230 |
Why?
| Female | 24 | 2018 | 59581 | 0.230 |
Why?
| Intracellular Signaling Peptides and Proteins | 2 | 2006 | 386 | 0.230 |
Why?
| Aged | 11 | 2016 | 19122 | 0.230 |
Why?
| Adrenergic alpha-Antagonists | 2 | 2002 | 30 | 0.220 |
Why?
| Colonic Neoplasms | 2 | 2016 | 222 | 0.220 |
Why?
| Middle Aged | 12 | 2016 | 26806 | 0.210 |
Why?
| Genetic Predisposition to Disease | 1 | 2011 | 2102 | 0.210 |
Why?
| Proto-Oncogene Proteins c-akt | 7 | 2018 | 400 | 0.210 |
Why?
| Proto-Oncogene Proteins c-raf | 1 | 2002 | 43 | 0.210 |
Why?
| Adrenergic alpha-Agonists | 1 | 2002 | 29 | 0.210 |
Why?
| Neuroimmunomodulation | 1 | 2002 | 70 | 0.200 |
Why?
| ras Proteins | 3 | 2013 | 138 | 0.200 |
Why?
| Adrenergic beta-Agonists | 1 | 2002 | 126 | 0.190 |
Why?
| Adult | 11 | 2016 | 30608 | 0.190 |
Why?
| Adrenergic beta-Antagonists | 2 | 2002 | 288 | 0.190 |
Why?
| Mice, Inbred BALB C | 9 | 2003 | 1153 | 0.180 |
Why?
| Polymorphism, Single Nucleotide | 4 | 2011 | 1893 | 0.180 |
Why?
| Hemoptysis | 1 | 2000 | 35 | 0.180 |
Why?
| Head and Neck Neoplasms | 2 | 2016 | 436 | 0.180 |
Why?
| In Situ Hybridization, Fluorescence | 2 | 2012 | 314 | 0.170 |
Why?
| Cytokines | 4 | 2005 | 1843 | 0.170 |
Why?
| Male | 22 | 2016 | 55663 | 0.170 |
Why?
| Carcinoma, Squamous Cell | 2 | 2016 | 584 | 0.170 |
Why?
| Cell Transformation, Neoplastic | 2 | 2018 | 312 | 0.160 |
Why?
| DNA Topoisomerases, Type II | 2 | 2016 | 44 | 0.160 |
Why?
| Transplantation, Heterologous | 2 | 2016 | 183 | 0.160 |
Why?
| CDC2 Protein Kinase | 1 | 2018 | 25 | 0.160 |
Why?
| MAP Kinase Kinase Kinases | 2 | 2015 | 68 | 0.150 |
Why?
| Case-Control Studies | 3 | 2011 | 3008 | 0.150 |
Why?
| Gene Expression Profiling | 4 | 2018 | 1523 | 0.150 |
Why?
| Oncogene Proteins v-abl | 1 | 2017 | 4 | 0.150 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 3 | 2010 | 113 | 0.150 |
Why?
| Proto-Oncogene Proteins p21(ras) | 5 | 2016 | 229 | 0.150 |
Why?
| Dasatinib | 1 | 2017 | 46 | 0.150 |
Why?
| Immunohistochemistry | 5 | 2017 | 1635 | 0.140 |
Why?
| Antigens, Neoplasm | 2 | 2016 | 222 | 0.140 |
Why?
| Adenocarcinoma | 2 | 2014 | 801 | 0.140 |
Why?
| Neoplasms | 3 | 2016 | 2106 | 0.140 |
Why?
| Angiogenesis Inhibitors | 2 | 2018 | 215 | 0.140 |
Why?
| Receptors, Cell Surface | 2 | 2012 | 354 | 0.140 |
Why?
| Neovascularization, Pathologic | 2 | 2018 | 283 | 0.140 |
Why?
| Cyclic AMP Response Element-Binding Protein | 3 | 2002 | 127 | 0.140 |
Why?
| Intercellular Signaling Peptides and Proteins | 2 | 2015 | 350 | 0.140 |
Why?
| Corynebacterium | 1 | 2017 | 36 | 0.140 |
Why?
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 27 | 0.140 |
Why?
| Aged, 80 and over | 5 | 2014 | 6364 | 0.140 |
Why?
| Neoplastic Stem Cells | 2 | 2018 | 334 | 0.140 |
Why?
| Corynebacterium Infections | 1 | 2017 | 31 | 0.140 |
Why?
| Axin Protein | 1 | 2016 | 18 | 0.130 |
Why?
| Cell Cycle | 5 | 2018 | 544 | 0.130 |
Why?
| Aurora Kinase A | 1 | 2016 | 52 | 0.130 |
Why?
| Neoplasms, Experimental | 1 | 2017 | 152 | 0.130 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2014 | 1361 | 0.130 |
Why?
| Transcription Factor 7-Like 2 Protein | 1 | 2016 | 24 | 0.130 |
Why?
| Autophagy | 1 | 2018 | 234 | 0.130 |
Why?
| RNA, Messenger | 5 | 2016 | 2559 | 0.130 |
Why?
| Genotype | 3 | 2012 | 1775 | 0.130 |
Why?
| RNA, Small Interfering | 2 | 2015 | 543 | 0.130 |
Why?
| Jagged-1 Protein | 1 | 2015 | 23 | 0.130 |
Why?
| Serrate-Jagged Proteins | 1 | 2015 | 28 | 0.130 |
Why?
| Drug Synergism | 2 | 2014 | 316 | 0.130 |
Why?
| Pyrazoles | 1 | 2018 | 364 | 0.130 |
Why?
| Gene Duplication | 1 | 2015 | 63 | 0.120 |
Why?
| Retinaldehyde | 1 | 2015 | 6 | 0.120 |
Why?
| Pyrimidinones | 1 | 2015 | 88 | 0.120 |
Why?
| HMGB1 Protein | 2 | 2007 | 48 | 0.120 |
Why?
| Respiration, Artificial | 2 | 2011 | 526 | 0.120 |
Why?
| Acetaldehyde | 1 | 2015 | 20 | 0.120 |
Why?
| Neoplasm Transplantation | 4 | 2016 | 232 | 0.120 |
Why?
| Acridines | 1 | 2014 | 7 | 0.120 |
Why?
| Topoisomerase II Inhibitors | 1 | 2014 | 23 | 0.120 |
Why?
| Pyridones | 1 | 2015 | 124 | 0.120 |
Why?
| Gene Expression Regulation | 2 | 2007 | 2324 | 0.110 |
Why?
| Cell Cycle Proteins | 1 | 2018 | 552 | 0.110 |
Why?
| Benzazepines | 1 | 2014 | 37 | 0.110 |
Why?
| Calcium-Binding Proteins | 1 | 2015 | 207 | 0.110 |
Why?
| Wnt Proteins | 1 | 2015 | 135 | 0.110 |
Why?
| Cellular Senescence | 1 | 2015 | 153 | 0.110 |
Why?
| Disease Models, Animal | 4 | 2018 | 3549 | 0.110 |
Why?
| Cell Growth Processes | 1 | 2013 | 51 | 0.110 |
Why?
| Carcinoma, Pancreatic Ductal | 1 | 2016 | 212 | 0.110 |
Why?
| DNA-Binding Proteins | 3 | 2016 | 1317 | 0.110 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 282 | 0.100 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2012 | 9 | 0.100 |
Why?
| Molecular Targeted Therapy | 1 | 2015 | 347 | 0.100 |
Why?
| Cyclosporine | 1 | 2013 | 161 | 0.100 |
Why?
| Random Allocation | 1 | 2013 | 335 | 0.100 |
Why?
| p38 Mitogen-Activated Protein Kinases | 5 | 2007 | 262 | 0.100 |
Why?
| Gene Knockdown Techniques | 1 | 2013 | 299 | 0.100 |
Why?
| Enzyme Activation | 6 | 2003 | 790 | 0.100 |
Why?
| Chemokine CXCL12 | 1 | 2012 | 74 | 0.100 |
Why?
| Aldehyde Dehydrogenase, Mitochondrial | 3 | 2017 | 33 | 0.100 |
Why?
| Melanoma | 1 | 2018 | 631 | 0.100 |
Why?
| Prognosis | 3 | 2015 | 3344 | 0.100 |
Why?
| Receptors, CXCR4 | 1 | 2012 | 78 | 0.100 |
Why?
| Lung | 8 | 2004 | 3593 | 0.100 |
Why?
| Linkage Disequilibrium | 2 | 2012 | 245 | 0.100 |
Why?
| Immunoprecipitation | 1 | 2012 | 152 | 0.100 |
Why?
| Lung Diseases | 3 | 2004 | 703 | 0.100 |
Why?
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 666 | 0.100 |
Why?
| Hydroxamic Acids | 1 | 2011 | 80 | 0.100 |
Why?
| Peroxidase | 2 | 2002 | 157 | 0.090 |
Why?
| Sirolimus | 1 | 2012 | 181 | 0.090 |
Why?
| Drug Design | 1 | 2012 | 151 | 0.090 |
Why?
| Genetic Markers | 1 | 2012 | 322 | 0.090 |
Why?
| PTEN Phosphohydrolase | 1 | 2012 | 140 | 0.090 |
Why?
| Genetic Association Studies | 1 | 2012 | 345 | 0.090 |
Why?
| Administration, Oral | 1 | 2012 | 731 | 0.090 |
Why?
| Histone Deacetylase Inhibitors | 1 | 2011 | 198 | 0.090 |
Why?
| Phosphorylation | 3 | 2018 | 1572 | 0.090 |
Why?
| Cetuximab | 3 | 2016 | 91 | 0.080 |
Why?
| Membrane Proteins | 1 | 2015 | 1022 | 0.080 |
Why?
| Cell Separation | 1 | 2010 | 292 | 0.080 |
Why?
| Gene Expression Regulation, Neoplastic | 4 | 2016 | 1148 | 0.080 |
Why?
| Antibodies, Monoclonal | 1 | 2015 | 1270 | 0.080 |
Why?
| G2 Phase Cell Cycle Checkpoints | 2 | 2018 | 41 | 0.080 |
Why?
| Models, Statistical | 1 | 2012 | 604 | 0.080 |
Why?
| Chemokines | 4 | 2003 | 213 | 0.080 |
Why?
| Genetic Variation | 2 | 2012 | 876 | 0.070 |
Why?
| Cells, Cultured | 6 | 2007 | 3897 | 0.070 |
Why?
| Chemokine CXCL2 | 3 | 2001 | 37 | 0.070 |
Why?
| Clinical Trials as Topic | 2 | 2015 | 934 | 0.070 |
Why?
| Europe | 1 | 2007 | 336 | 0.070 |
Why?
| HT29 Cells | 2 | 2018 | 36 | 0.070 |
Why?
| Gene Expression | 2 | 2003 | 1422 | 0.070 |
Why?
| Flow Cytometry | 1 | 2010 | 1087 | 0.070 |
Why?
| ErbB Receptors | 3 | 2016 | 561 | 0.070 |
Why?
| Genome, Human | 1 | 2008 | 352 | 0.070 |
Why?
| Adolescent | 3 | 2011 | 17829 | 0.070 |
Why?
| Thymine | 1 | 2006 | 12 | 0.070 |
Why?
| Interleukin-1 Receptor-Associated Kinases | 1 | 2006 | 20 | 0.070 |
Why?
| Cytosine | 1 | 2006 | 45 | 0.070 |
Why?
| Tumor Burden | 2 | 2018 | 262 | 0.070 |
Why?
| MicroRNAs | 1 | 2012 | 601 | 0.070 |
Why?
| Phentolamine | 2 | 2002 | 17 | 0.060 |
Why?
| Translocation, Genetic | 1 | 2006 | 94 | 0.060 |
Why?
| Inflammation Mediators | 2 | 2006 | 476 | 0.060 |
Why?
| Homozygote | 1 | 2006 | 188 | 0.060 |
Why?
| MAP Kinase Kinase 2 | 2 | 2002 | 27 | 0.060 |
Why?
| Cell Nucleus | 2 | 2006 | 554 | 0.060 |
Why?
| Spheroids, Cellular | 2 | 2016 | 58 | 0.060 |
Why?
| Propranolol | 2 | 2002 | 53 | 0.060 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 929 | 0.060 |
Why?
| Survival Analysis | 1 | 2008 | 1220 | 0.060 |
Why?
| Models, Biological | 2 | 2018 | 1630 | 0.060 |
Why?
| MAP Kinase Kinase 1 | 2 | 2002 | 66 | 0.060 |
Why?
| Introns | 1 | 2006 | 227 | 0.060 |
Why?
| Exons | 1 | 2006 | 303 | 0.060 |
Why?
| Heat-Shock Proteins | 1 | 2005 | 113 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 2 | 2002 | 146 | 0.060 |
Why?
| Neoplasm Invasiveness | 2 | 2016 | 445 | 0.060 |
Why?
| Bone Marrow Cells | 2 | 2003 | 267 | 0.060 |
Why?
| Cause of Death | 1 | 2006 | 363 | 0.060 |
Why?
| Shock, Septic | 1 | 2006 | 185 | 0.060 |
Why?
| Positron-Emission Tomography | 2 | 2018 | 265 | 0.060 |
Why?
| Oxidants | 1 | 2003 | 112 | 0.050 |
Why?
| Ribosomal Protein S6 Kinases | 1 | 2002 | 21 | 0.050 |
Why?
| Brimonidine Tartrate | 1 | 2002 | 9 | 0.050 |
Why?
| Models, Genetic | 1 | 2005 | 565 | 0.050 |
Why?
| Phenylephrine | 1 | 2002 | 74 | 0.050 |
Why?
| Transcription, Genetic | 2 | 2006 | 1317 | 0.050 |
Why?
| RNA Interference | 2 | 2016 | 437 | 0.050 |
Why?
| Lung Neoplasms | 1 | 2015 | 2223 | 0.050 |
Why?
| Hydrogen Peroxide | 1 | 2003 | 287 | 0.050 |
Why?
| Quinoxalines | 1 | 2002 | 60 | 0.050 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2004 | 1134 | 0.050 |
Why?
| Protein-Tyrosine Kinases | 2 | 2002 | 399 | 0.050 |
Why?
| Membrane Glycoproteins | 1 | 2004 | 429 | 0.050 |
Why?
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 130 | 0.050 |
Why?
| Free Radical Scavengers | 1 | 2001 | 78 | 0.050 |
Why?
| MAP Kinase Signaling System | 1 | 2002 | 276 | 0.050 |
Why?
| Transcriptome | 2 | 2016 | 728 | 0.050 |
Why?
| High Mobility Group Proteins | 1 | 2000 | 49 | 0.040 |
Why?
| Nuclear Proteins | 2 | 2001 | 593 | 0.040 |
Why?
| Protein Processing, Post-Translational | 1 | 2002 | 399 | 0.040 |
Why?
| Neutropenia | 1 | 2000 | 125 | 0.040 |
Why?
| Interleukin-1 | 2 | 2000 | 966 | 0.040 |
Why?
| Adjuvants, Immunologic | 1 | 2000 | 206 | 0.040 |
Why?
| Colorado | 1 | 2008 | 4091 | 0.040 |
Why?
| Trans-Activators | 1 | 2001 | 368 | 0.040 |
Why?
| M Phase Cell Cycle Checkpoints | 1 | 2018 | 23 | 0.040 |
Why?
| Biomarkers | 1 | 2008 | 3418 | 0.040 |
Why?
| 4-Aminobenzoic Acid | 1 | 2018 | 6 | 0.040 |
Why?
| Up-Regulation | 2 | 2016 | 812 | 0.040 |
Why?
| Neoplasm Proteins | 2 | 2016 | 385 | 0.040 |
Why?
| Pneumonia | 1 | 2003 | 568 | 0.040 |
Why?
| Protein Transport | 1 | 2018 | 396 | 0.040 |
Why?
| Retinal Dehydrogenase | 1 | 2016 | 41 | 0.030 |
Why?
| Inhibitory Concentration 50 | 1 | 2016 | 75 | 0.030 |
Why?
| Prospective Studies | 1 | 2007 | 6218 | 0.030 |
Why?
| Hyaluronan Receptors | 1 | 2016 | 91 | 0.030 |
Why?
| Blotting, Western | 2 | 2013 | 1151 | 0.030 |
Why?
| Young Adult | 1 | 2011 | 10478 | 0.030 |
Why?
| Protein Interaction Maps | 1 | 2016 | 34 | 0.030 |
Why?
| Tissue Array Analysis | 1 | 2016 | 50 | 0.030 |
Why?
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2016 | 107 | 0.030 |
Why?
| Papillomaviridae | 1 | 2016 | 102 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2016 | 180 | 0.030 |
Why?
| Chromatin Immunoprecipitation | 1 | 2016 | 129 | 0.030 |
Why?
| Cadherins | 1 | 2016 | 176 | 0.030 |
Why?
| S-Phase Kinase-Associated Proteins | 1 | 2015 | 18 | 0.030 |
Why?
| Inflammation | 1 | 2005 | 2485 | 0.030 |
Why?
| Diphenylamine | 1 | 2014 | 6 | 0.030 |
Why?
| Iloprost | 1 | 2015 | 46 | 0.030 |
Why?
| Acid Phosphatase | 1 | 2014 | 17 | 0.030 |
Why?
| Rhodamines | 1 | 2014 | 17 | 0.030 |
Why?
| Retrospective Studies | 1 | 2011 | 12544 | 0.030 |
Why?
| Tumor Cells, Cultured | 1 | 2016 | 855 | 0.030 |
Why?
| G2 Phase | 1 | 2014 | 31 | 0.030 |
Why?
| Cell Division | 1 | 2016 | 759 | 0.030 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2016 | 271 | 0.030 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2016 | 168 | 0.030 |
Why?
| Mice, Inbred C57BL | 3 | 2015 | 4719 | 0.030 |
Why?
| Sequence Analysis, RNA | 1 | 2016 | 390 | 0.030 |
Why?
| Antigens, CD | 1 | 2016 | 443 | 0.030 |
Why?
| Benzamides | 1 | 2014 | 169 | 0.030 |
Why?
| Tretinoin | 1 | 2015 | 125 | 0.030 |
Why?
| Transfection | 1 | 2016 | 870 | 0.030 |
Why?
| Receptor, Notch2 | 1 | 2013 | 14 | 0.030 |
Why?
| Gonanes | 1 | 2013 | 27 | 0.030 |
Why?
| Protein Binding | 1 | 2018 | 1897 | 0.030 |
Why?
| Alphapapillomavirus | 1 | 2013 | 36 | 0.030 |
Why?
| Receptors, CXCR | 1 | 2012 | 2 | 0.030 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2016 | 447 | 0.030 |
Why?
| Erlotinib Hydrochloride | 1 | 2012 | 65 | 0.030 |
Why?
| Cyclin D1 | 1 | 2012 | 61 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2014 | 623 | 0.030 |
Why?
| Active Transport, Cell Nucleus | 2 | 2003 | 110 | 0.030 |
Why?
| Mice, Knockout | 3 | 2003 | 2587 | 0.030 |
Why?
| Computers | 1 | 2012 | 60 | 0.030 |
Why?
| Mice, Inbred C3H | 2 | 2004 | 242 | 0.020 |
Why?
| Niacinamide | 1 | 2012 | 64 | 0.020 |
Why?
| Maximum Tolerated Dose | 1 | 2012 | 184 | 0.020 |
Why?
| Tissue Distribution | 1 | 2012 | 285 | 0.020 |
Why?
| Phenylurea Compounds | 1 | 2012 | 84 | 0.020 |
Why?
| United States | 1 | 2007 | 12211 | 0.020 |
Why?
| Proto-Oncogene Proteins c-myc | 1 | 2012 | 115 | 0.020 |
Why?
| Calcium Signaling | 1 | 2013 | 213 | 0.020 |
Why?
| Injections, Intraperitoneal | 2 | 2001 | 100 | 0.020 |
Why?
| Xanthine Oxidase | 2 | 2001 | 71 | 0.020 |
Why?
| Acute Disease | 2 | 2004 | 915 | 0.020 |
Why?
| Cluster Analysis | 1 | 2011 | 460 | 0.020 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2011 | 238 | 0.020 |
Why?
| Survival Rate | 1 | 2014 | 1644 | 0.020 |
Why?
| Ligands | 1 | 2011 | 565 | 0.020 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 499 | 0.020 |
Why?
| Models, Molecular | 1 | 2014 | 1379 | 0.020 |
Why?
| Tumor Microenvironment | 1 | 2012 | 434 | 0.020 |
Why?
| Computational Biology | 1 | 2013 | 531 | 0.020 |
Why?
| Dose-Response Relationship, Drug | 1 | 2012 | 1856 | 0.020 |
Why?
| Cell Movement | 1 | 2011 | 867 | 0.020 |
Why?
| Adiposity | 1 | 2012 | 457 | 0.020 |
Why?
| Calcium | 1 | 2013 | 1104 | 0.020 |
Why?
| Mice, Transgenic | 2 | 2003 | 1953 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2018 | 3053 | 0.020 |
Why?
| Oxidative Stress | 2 | 2003 | 1084 | 0.020 |
Why?
| Neutrophil Infiltration | 1 | 2004 | 94 | 0.010 |
Why?
| Permeability | 1 | 2004 | 148 | 0.010 |
Why?
| Transcription Factor AP-1 | 1 | 2003 | 80 | 0.010 |
Why?
| Algorithms | 1 | 2010 | 1474 | 0.010 |
Why?
| Phosphotransferases | 1 | 2003 | 25 | 0.010 |
Why?
| Reproducibility of Results | 1 | 2010 | 2770 | 0.010 |
Why?
| Toll-Like Receptors | 1 | 2004 | 166 | 0.010 |
Why?
| Aconitate Hydratase | 1 | 2003 | 16 | 0.010 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2003 | 144 | 0.010 |
Why?
| Lipid Peroxidation | 1 | 2003 | 139 | 0.010 |
Why?
| Extracellular Space | 1 | 2003 | 117 | 0.010 |
Why?
| Metalloporphyrins | 1 | 2003 | 104 | 0.010 |
Why?
| Replication Protein C | 1 | 2001 | 4 | 0.010 |
Why?
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2001 | 11 | 0.010 |
Why?
| Biological Transport | 1 | 2003 | 372 | 0.010 |
Why?
| bcl-X Protein | 1 | 2001 | 38 | 0.010 |
Why?
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2001 | 22 | 0.010 |
Why?
| Cysteine Endopeptidases | 1 | 2001 | 60 | 0.010 |
Why?
| Protein Kinases | 1 | 2003 | 307 | 0.010 |
Why?
| CREB-Binding Protein | 1 | 2001 | 27 | 0.010 |
Why?
| Toll-Like Receptor 4 | 1 | 2004 | 286 | 0.010 |
Why?
| Transcription Factor RelA | 1 | 2001 | 83 | 0.010 |
Why?
| Tungsten | 1 | 2001 | 26 | 0.010 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2001 | 164 | 0.010 |
Why?
| Animal Feed | 1 | 2001 | 49 | 0.010 |
Why?
| Immune Sera | 1 | 2000 | 79 | 0.010 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2001 | 213 | 0.010 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 164 | 0.010 |
Why?
| Organ Specificity | 1 | 2000 | 270 | 0.010 |
Why?
| Protein Biosynthesis | 1 | 2001 | 385 | 0.010 |
Why?
| Endotoxins | 1 | 2000 | 204 | 0.010 |
Why?
| Antioxidants | 1 | 2003 | 530 | 0.010 |
Why?
| Intubation, Intratracheal | 1 | 2000 | 215 | 0.010 |
Why?
| Treatment Outcome | 1 | 2010 | 9105 | 0.010 |
Why?
| Peptides | 1 | 2001 | 848 | 0.010 |
Why?
| Proteins | 1 | 2001 | 912 | 0.010 |
Why?
|
|
Arcaroli's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|